Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.

Imaxio has announced that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313.

The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University.

Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used.

IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates.

It is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.

Tuberculosis remains a significant cause of mortality and morbidity throughout the developing world. Worldwide, there are two million deaths each year from TB. It is estimated that a third of the world’s population is latently infected with Mycobacterium tuberculosis, the bacteria responsible for tuberculosis.

The HIV epidemic and the emergence of multi-drug resistant strains of TB have made the need for improved tuberculosis control even more urgent.

As the currently available vaccine, BCG, is largely ineffective at protecting against adult pulmonary disease in endemic areas, the MVA85A vaccine candidate has been designed to enhance BCG’s protective efficacy.

Though first studies of MVA85A were promising, a recent phase II clinical trial revealed that the vaccine candidate did not offer extra protection against TB in South African infants who had already received the BCG vaccine.

The Jenner Institute is investigating a number of options to see if the immune response generated by MVA85A can be improved.

The Jenner Institute identified IMX313 as one of the best vaccine technologies to enhance immune responses in a comparison study funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative. It is now starting to evaluate it in humans in combination with MVA85A.

“Following a number of successes with IMX313 in preclinical trials, we are really pleased to have reached this milestone: the first administration of IMX313 in humans,” explains Dr. Fergal Hill, chief scientific officer of Imaxio. “We believe strongly that this will confirm fully that IMX313 is a real solution for developing more effective human vaccines and for addressing major infectious diseases.”

“We are keen to find out whether this novel vaccine candidate will pave the way for new successes in addressing tuberculosis,” said Prof. Helen McShane, tuberculosis program leader and professor of vaccinology at the Jenner Institute at Oxford University. “We think IMX313 may be a key component to help MVA85A show even greater potency in humans.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop Staphylococcus Aureus Vaccine
A consortium has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Wednesday, July 03, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop S. aureus Vaccine
A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Tuesday, July 02, 2013
Scientific News
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Scroll Up
Scroll Down

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos